

Table 2. Demographic, clinical and biochemical characteristics of responders vs non-responders to somatostatin analogues in terms of tumor size reduction

	Responders n=24	Non Responders n=31	P-value
Women (%)	16 (66.7)	21 (67.7)	0.830
Macroadenomas (%)	20 (83.3)	16 (51.6)	0.030
Age (years)	52.8±12.8	51.6±11.4	0.722
Surgery (%)	5(20.8)	10(32.5)	0.511
Duration of treatment (months)	51.9±41.7	45.0±43.2	0.274
GH before treatment (µg/l)	20.2±16.6	13.2±11.9	0.043
GH under treatment (µg/l)	2.5±21.6	3.7±4.48	0.212
IGF1 before treatment (µg/l)	669±183	665±293	0.930
IGF1 under treatment (µg/l)	279±171.5	381±268.8	0.094
Tumor size before treatment (mm)	17.1±9.8	10.5±7.8	<0.001
Acromegaly control [GH <2.5 µg/l and normal IGF1](%)	17 (70.8)	8(25.8)	<0.001